A Phase 3 interventional study of recombinant human erythropoietin and recombinant human erythropoietin placebo in Chemotherapy Induced Anemia, sponsored by Chugai Pharmaceutical. Completed. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2009-02-02.
Sponsored by Chugai Pharmaceutical · Phase 3, Interventional, and Treatment
To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy
Chugai Pharmaceutical is the lead sponsor of 63 studies on the registry; 7 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: recombinant human erythropoietin
Drug: recombinant human erythropoietin placebo
36000IU（0.5mL）s.c./week for 8 weeks
0 IU(0.5mL)s.c./week for 8 weeks
The increase in Hb concentration
Time frame: week 8
Changes in QOL scores
Time frame: 8 weeks
No study locations are listed for this record.
This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chugai Pharmaceutical